These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31850422)

  • 1. Recognition of PDL1/L2 by different induced-fit mechanisms of PD1: a comparative study of molecular dynamics simulations.
    Lyu N; Wang K; Zhang F; Qin H; Zhao Y; Wu R; Si Y; Wang L
    Phys Chem Chem Phys; 2020 Jan; 22(3):1276-1287. PubMed ID: 31850422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the conformational dynamics of PD1 in complex with different ligands: What we can learn for designing novel PD1 signaling blockers?
    Ponce LF; García-Martínez K; León K; Valiente PA
    Proteins; 2021 Feb; 89(2):141-148. PubMed ID: 32862461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling a Conserved Conformation of the FG Loop upon the Binding of Natural Ligands to the Human and Murine PD1.
    Ponce LF; Leon K; Valiente PA
    J Phys Chem B; 2022 Feb; 126(7):1441-1446. PubMed ID: 35167293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
    Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
    Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.
    Leng C; Li Y; Qin J; Ma J; Liu X; Cui Y; Sun H; Wang Z; Hua X; Yu Y; Li H; Zhang J; Zheng Y; Wang W; Zhu J; Wang Q
    Oncol Rep; 2016 Feb; 35(2):699-708. PubMed ID: 26718132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploiting the Innate Plasticity of the Programmed Cell Death-1 (PD1) Receptor to Design Pembrolizumab H3 Loop Mimics.
    Richaud AD; Zaghouani M; Zhao G; Wangpaichitr M; Savaraj N; Roche SP
    Chembiochem; 2022 Nov; 23(21):e202200449. PubMed ID: 36082509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting a Stable Dimeric Form of the PD1-PDL1 Complex: Implications for Understanding the PD1 Activation Mechanism.
    Ponce LF; Ramírez-Echemendia DP; León K; Valiente PA
    J Phys Chem B; 2023 Jul; 127(26):5764-5771. PubMed ID: 37343227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using phage-assisted continuous evolution (PACE) to evolve human PD1.
    Ye X; Tu M; Piao M; Yang L; Zhou Z; Li Z; Lin M; Yang Z; Zuo Z
    Exp Cell Res; 2020 Nov; 396(1):112244. PubMed ID: 32860814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanobody against PDL1.
    Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
    Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
    Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
    MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.
    Xing X; Guo J; Ding G; Li B; Dong B; Feng Q; Li S; Zhang J; Ying X; Cheng X; Guo T; Du H; Hu Y; Zhou T; Wang X; Li L; Li Q; Xie M; Li L; Gao X; Shan F; Li Z; Jia S; Wen X; Wang J; Ji J
    Oncoimmunology; 2018; 7(3):e1356144. PubMed ID: 29399387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of PD‑L1 and PD‑L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non‑small cell lung cancer.
    Sumitomo R; Huang CL; Fujita M; Cho H; Date H
    Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35169863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery.
    Tang S; Kim PS
    Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24500-24506. PubMed ID: 31727844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing protein flexibility reveals a mechanism for selective promiscuity.
    Pabon NA; Camacho CJ
    Elife; 2017 Apr; 6():. PubMed ID: 28432789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
    Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer.
    Kaufman B; Abramov O; Ievko A; Apple D; Shlapobersky M; Allon I; Greenshpan Y; Bhattachrya B; Cohen O; Charkovsky T; Gayster A; Shaco-Levy R; Rouvinov K; Livoff A; Elkabets M; Porgador A
    Sci Adv; 2023 May; 9(21):eadg2809. PubMed ID: 37235664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed cell death 1 and programmed cell death ligand 1 expression in invasive breast carcinoma using CAL10 and NAT105 immunostaining.
    Durak Ö; Bozkurt KK; Çiriş İM; Kocer M; Eroğlu HE
    Biotech Histochem; 2023 Feb; 98(2):147-154. PubMed ID: 36281760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke.
    Seifert HA; Zhu W; Vandenbark AA; Alkayed NJ; Offner H
    Metab Brain Dis; 2019 Dec; 34(6):1705-1712. PubMed ID: 31410774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower PDL1, PDL2, and AXL Expression on Lung Myeloid Cells Suggests Inflammatory Bias in Smoking and Chronic Obstructive Pulmonary Disease.
    Vasudevan S; Vásquez JJ; Chen W; Aguilar-Rodriguez B; Niemi EC; Zeng S; Tamaki W; Nakamura MC; Arjomandi M
    Am J Respir Cell Mol Biol; 2020 Dec; 63(6):780-793. PubMed ID: 32915645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.